Document is current
Any future updates will be listed below
-
Authors
Arzika, Ahmed M.
Amza, Abdou
Ousmane, Sani
Maliki, Ramatou
Almou, Ibrahim
Galo, Nasser
Harouna, Nasser
Mankara, Alio
Aichatou, Bawa
Boubacar, Ousseini
Lebas, Elodie
Peterson, Brittany
Brandt, Carolyn
Picariello, Andrea
Cheng, Angela
Porco, Travis C.
Doan, Thuy
Arnold, Benjamin F.
Lietman, Thomas M.
O’Brien, Kieran S.
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation (INV-062291)
National Institute of Allergy and Infectious Diseases (R01AI175250)
- License Information
-
More Information
Article History
Received: 17 June 2025
Accepted: 9 February 2026
First Online: 18 February 2026
Declarations
:
: The University of California San Francisco Institutional Review Board has given ethical approval for the trial and will review the trial annually (23-39839). The Comité National Éthique pour la Recherche en Santé in Niger granted ethical approval before study activities began (DELIBERATION No. 14/2024/CNERS). Verbal informed consent will be obtained from the head of household for participation in the census and from caregiver/guardians for treatment administration and outcome data collection, as is standard for studies of mass drug administration in this setting. Verbal consent will be obtained from regional, district, and community leaders before recruiting any participants into the study. Consent and refusals will be tracked in the data collection systems for each activity. There is no financial cost to the participant and there is no reimbursement for overall participation in this study.
: No data have been included in this study protocol. No details, images, or videos relating to individuals have been included. The authors will provide the verbal consent scripts used in this study upon request.
: The authors declare that they have no competing interests.
